BTIG says Globus Medical’s (GMED) announced acquisition of Nevro (NVRO) “is surprising on the surface.” Investors did not expect Globus would ...

BTIG analyst Andrew Harte lowered the firm’s price target on Lightspeed (LSPD) to $17 from $21 and keeps a Buy rating on the shares. The shares ...

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced its ...

BTIG analyst Justin Zelin downgraded Kura Oncology stock (NASDAQ:KURA) from Buy to Neutral. Zelin cited concerns over the recent KOMET-001 study results for the company's drug, ziftomenib. The ...

BTIG analyst Gregory Lewis (JO:LEWJ) revised the price target for Blue Bird Corp (NASDAQ:BLBD) shares to $45.00, down from the previous target of $55.00, while reaffirming a Buy rating on the stock.

BTIG Research lowered shares of IQVIA (NYSE:IQV – Free Report) from a buy rating to a neutral rating in a research report report published on Monday morning, Marketbeat.com reports. Several other ...

This partnership addresses the growing demand among institutional traders for advanced, centralised technology that enables ...

Treace provides technology that facilitates Lapiplasty bunion surgery and related midfoot deformities. The company recently ...

But before that let's have a chartist view from BTIG's technical guru Jonathan Krinsky. He notes that the S&P 500's rally off this week's lows is quite impressive and sets up the stock barometer ...

Analysts at BTIG moved to the sidelines on online dating apps company Match Group (NASDAQ:MTCH) and lowered its investment rating to "Neutral" from "Buy" on Tuesday. The research firm said its ...